Scotiabank Initiates Outperform on Gossamer Bio (GOSS) with an $11 PT, Highlights Potential of PAH Drug Seralutinib

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the biotech stocks to buy according to Wall Street analysts. On July 14, Scotiabank initiated coverage of Gossamer Bio with an Outperform rating and an $11 price target. The firm is optimistic about Gossamer Bio’s approach to treating pulmonary arterial hypertension/PAH and pulmonary hypertension associated with interstitial lung disease/PH-ILD.

Scotiabank highlighted seralutinib, which is Gossamer’s lead asset, for its potential to achieve significant market uptake due to its novel mechanism of action as an inhaled tyrosine kinase inhibitor. Seralutinib targets multiple growth factor receptors (PDGFRα/β, CSF1R, and c-KIT) implicated in PAH pathogenesis and is designed for direct delivery to the lungs via a dry powder inhaler. The firm views seralutinib as a complementary treatment to existing standard care.

Scotiabank Initiates Outperform on Gossamer Bio (GOSS) with an $11 PT, Highlights Potential of PAH Drug Seralutinib

A closeup of a medical technician handling a sample of a biopharmaceutical drug.

A significant business development for Gossamer Bio earlier in Q1 2025 is the completion of new patient screening for the PROSERA study, which is its registrational Phase 3 trial for seralutinib in PAH. It closed enrollment on June 11 and reached a total of 390 patients. However, the timeline for announcing top-line results from the PROSERA study has been pushed to February 2026.

Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension/PAH in the US.

While we acknowledge the potential of GOSS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GOSS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.